Vascular endothelial growth factor and angiogenesis

…, MS Highley, H Wildiers, AT Van Oosterom… - Pharmacological …, 2004 - ASPET
at one end [strands b4 (67–69) and b7 (103–105)], and a short three-stranded b-sheet [strands
b2 (46–49), b5, and b6] at the … VEGF-A exists in at least seven homodimeric isoforms. The …

Soft tissue sarcomas of adults: state of the translational science

…, S Singer, M Sundaram, AT Van Oosterom… - Clinical cancer …, 2003 - AACR
… Subsequently, it was found that patients with small high-grade tumors undergoing primary
treatment at referral institutions had an overall metastasis-free survival of 90%, placing them in …

New guidelines to evaluate the response to treatment in solid tumors

…, M Van Glabbeke, AT van Oosterom… - Journal of the …, 2000 - academic.oup.com
at baseline to which subsequent measurements will be compared. Only patients with measurable
disease at … Measurable disease is defined by the presence of at least one measurable …

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

GD Demetri, AT van Oosterom, CR Garrett… - The Lancet, 2006 - thelancet.com
… was done at least at baseline screening, on day 28 of all treatment cycles, and at the end of
… the last time the performance status was no worse than at baseline or to death from cancer). …

Oxidative DNA damage: biological significance and methods of analysis

…, GD Boeck, M Highley, AT van Oosterom… - Critical reviews in …, 2002 - Taylor & Francis
… Reactive is not always an appropriate term; H2O2 and (O2)– react at diffusion controlled
rates with very few molecules, whereas (OH) reacts at diffusioncontrolled rates with almost …

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

AT van Oosterom, I Judson, J Verweij, S Stroobants… - The Lancet, 2001 - thelancet.com
… Of the other 11 patients, eight achieved a complete response on PET at day 8, which was
confirmed at day 29. Two patients had a partial response on day 8, followed by a complete …

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

…, P Hohenberger, AT van Oosterom… - European journal of …, 2006 - Elsevier
… Patients still alive and progression-free at the time of the analysis have been censored at
Median follow-up at the time of the present analysis was 33 months; 99%, 81% and 30% of the …

Randomized phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte …

…, C Théodore, SD Fossa, AT Van Oosterom… - Journal of Clinical …, 2001 - ascopubs.org
… RESULTS: Using an intent-to-treat analysis, at a median follow-up of 38 months, on the
HD-MVAC arm there were 28 complete responses (CRs) (21%) and 55 partial … AT van Oosterom

[PDF][PDF] Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line …

M Van Glabbeke, AT Van Oosterom… - Journal of Clinical …, 1999 - core.ac.uk
PURPOSE: A total of 2,185 patients with advanced soft tissue sarcomas who had been
treated in seven clinical trials investigating the use of doxorubicin-or epirubicin-containing …

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and …

…, M Van Glabbeke, AT Van Oosterom - European journal of …, 2004 - Elsevier
… Interestingly, while the median event-free survival time for the whole group at 104 weeks of
… the Phase I trial at doses of up to 500 mg twice daily and in the Phase II study at 400 mg twice …